NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma

Table 1 Correlation between NAP1L1 expression and clinicopathologic characteristics (n = 304)

Variable	No.	NAP1L1 expression levels		p value
Variable	No.	Low	High	p value
Age (years)
< 50	159	78	81
≥ 50	145	92	53	0.012
Gender
Female	32	17	15
Male	272	153	119	0.736
Serum AFP (ng/ml)
< 400	165	109	56
≥ 400	139	61	78	< 0.001
Cirrhosis
No	102	61	41
Yes	202	109	93	0.333
Tumor size (cm)
< 5	170	115	55
≥ 5	134	55	79	< 0.001
Tumor number
Solitary	233	138	95
Multiple	71	32	39	0.035
HbsAg
No	28	22	6
Yes	276	148	128	0.011
Microvascular invasion
No	200	119	81
Yes	104	51	53	0.081
BCLC stage
0–A	228	140	88
B–C	76	30	46	0.001
TNM stage
I–II	219	133	86
III–IV	85	37	48	0.007

ISSN: 1475-2867